<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/style.css">
    <link rel="stylesheet" href="./css/header.css">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
    <title>Sepraxa</title>
</head>
<body>
    <header>
        <div class="q-head-logo-wrap">
            <a class="q-head-nav" href="#home">
                Sepraxa
            </a>
        </div>
        <div class="q-head-nav-wrap">
            <a class="q-head-nav" href="#home">
                Home
            </a>
            <a class="q-head-nav" href="#secondPart">
                Discover
            </a>
            <a class="q-head-nav" href="#thirdPart">
                Benefits
            </a>
        </div>
    </header>
    <section class="landing">
        <div class="leftText">
            <div class="text">
                <div class="wrapper">
                    <div class="headline">
                        <h2>Sepsis Can’t Wait.</h2> <br>
                        <h2>Sepraxa is Ready.</h2>
                    </div>
                    <p class="subText">
                        Transform sepsis care. Improve outcomes. Save lives.
                    </p>
                </div>
            </div>

            <div>
                <img src="assets/SVG/drugsHaww.svg" alt="" class="heroImage">
            </div>
        </div>
        
        <section class="secondPart">
            <div class="secondTitles headline">
                <h2>Discover Sepraxa</h2>
            </div>
            <section class="theWhyCards">
                <div class="card">
                    <div class="card_title">Why Sepraxa?</div>
                    <div class="card_snippet">
                        <span>Sepraxa (seproxatil) </span>is the first-in-class <span>oral TLR4 inhibitor</span> for sepsis, offering <span>targeted anti-inflammatory action</span> without immunosuppression. Designed for critically ill patients, it’s a <span>safe, precise, and oral</span> breakthrough in sepsis care.
                    </div>
                </div>
                <div class="card">
                    <div class="card_title">Clinical Highlights</div>
                    <div class="card_snippet">
                        Sepraxa reduced 28-day mortality by <span>20%</span> in the Phase III PULSE-3 trial. It improved SOFA scores <span>(Δ = -6)</span>, shortened ICU stays by <span>3 days</span>, and reduced overall hospital time. Effective against both <span>gram-negative and gram-positive</span> infections.
                    </div>
                </div>
                <div class="card">
                    <div class="card_title">How to Administer</div>
                    <div class="card_snippet">
                        Sepraxa is given as a <span>150 mg oral tablet once daily for 7 days</span>. It has <span>no food restrictions</span>, with proven bioequivalence in both fasted and fed states. With <span>no IV required</span>, it's ideal for <span>ICU, step-down, and emergency settings</span>.
                    </div>
                </div>
            </section>
        </section>
        
        
        
        <section class="thirdPart">
            <div class="secondTitles headline">
                <h2>What Makes Sepraxa Stand Out</h2>
            </div>
            <section class="theWhyCards">
                <div class="card reasonCard">
                    <div class="card_snippet">
                        <div class="reason">
                            <img src="./assets/SVG/check-circle.svg" alt="">
                            <div class="reasonText">
                                No immunosuppression: Normal WBC and neutrophil counts maintained
                            </div>
                        </div>
                    </div>
                </div>
                <div class="card reasonCard">
                    <div class="card_snippet">
                        <div class="reason">
                            <img src="./assets/SVG/check-circle.svg" alt="">
                            <div class="reasonText">
                                Low adverse event rate (< 2%), mostly mild (e.g., nausea)
                            </div>
                        </div>
                    </div>
                </div>
                <div class="card reasonCard">
                    <div class="card_snippet">
                        <div class="reason">
                            <img src="./assets/SVG/check-circle.svg" alt="">
                            <div class="reasonText">
                                No liver or renal toxicity; ALT <40 U/L in sterile sepsis models
                            </div>
                        </div>
                    </div>
                </div>
            </section>
        </section>
        
        <section class="footer">
            <section class="theWhyCards">
                <div class="card footerCard">
                    <div class="card_snippet">
                        Project for BMD271 -  The Business of Pharmacology - 2024/25 <br>
                        Queen Mary University of London <br> <br>
                        Drug  Development Project: design all the steps required for the development
                        of a new drug, from target identification to approval <br> <br>
                        ~ A project and  website by Charmy Doshi<br>
                        230077540
                    </div>
                </div>
            </section>
        </section>
    </section>
</body>
</html>
